Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Pyc Therapeutics Limited currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. DANA H SHIN is the examiner assigned to this case. The action is situated in 1 distinct art unit. Since there is only 1 pending office action, the company's current patent office activity involves just 1 distinct examiner. DANA H SHIN is the sole official responsible for the company's 1 pending office action.
There are no other pending matters to diversify the company's risk within the Biotechnology & Pharmaceuticals sector. Because the portfolio consists of only 1 pending office action, the company's strategy must be perfectly aligned with the standards of the 1 distinct art unit involved. This single action represents the company's entire current footprint at the patent office. The company must ensure its arguments are perfectly tailored to the standards of DANA H SHIN to secure its intellectual property in the Biotechnology & Pharmaceuticals field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIN, DANA H | 1 | 26.9% | +26.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19636707 | COMPOSITIONS AND METHODS FOR TREATMENT OF MONOGENIC NEURODEVELOPMENT DISORDERS | SHIN, DANA H | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19636707 | COMPOSITIONS AND METHODS FOR TREATMENT OF MONOGENIC NEURODEVELOPMENT DISORDERS | SHIN, DANA H | — |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19636707 | COMPOSITIONS AND METHODS FOR TREATMENT OF MONOGENIC NEURODEVELOPMENT DISORDERS | SHIN, DANA H | 1635 | §103 | Non-Final OA | — | Pending | Apr 01, 2026 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPyc Therapeutics Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Dana H Shin has the most, with 1 of Pyc Therapeutics Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
